Johnson & Johnson said it expects to release its COVID-19 vaccine trial results within the next two weeks. But the company may not be able to produce as many doses for the federal government as originally expected. (The New York Times)

Amgen will pay $240 million for Michigan immunotherapy company Evoq Therapeutics’ molecules that target autoimmune disorders. The dendritic cells work to trigger immune tolerance in regulatory T cells. (Endpoints News)

Dollar General announced it would pay its employees to get a COVID-19 vaccine. “We don’t want our employees to have to choose between receiving a vaccine or coming into work,” the company said in a press release. (CNN)

Moderna CEO Stephane Bancel said Wednesday that COVID-19 will likely be around “forever.” Public health experts have warned in the past that the virus could become endemic, or present everywhere, indefinitely. (CNBC Weekly)

Sana Biotechnology plans to raise $150 million for an initial public offering, potentially bringing its market value up to more than $9 billion. The biotech firm is currently developing therapies for multiple sclerosis, Pelizaeus-Merzbacher disease and diabetes. (STAT)